Therapeutic potential of nanoparticles in the control of bacterial biofilms: a patent review
DOI:
https://doi.org/10.34188/bjaerv9n1-218Palavras-chave:
nanoparticles, nanocapsules, biofilm controlResumo
Objective: To evaluate patents that use nanotechnology as a strategy for the treatment of biofilms. Methods: A review of patents available in Espacenet from the European Patent Office and in the United States Patent and Trademark Office databases was conducted. The inclusion criteria were patents that mentioned the terms “nanomolecules,” “nanopharmaceuticals,” “nanocomposites,” or “nanocapsules” in combination with “biofilm” and “treatment”. Results: A total of 3,021 patents were screened, of which 2,565 were excluded because they were not relevant to this review. Among the remaining patents, 442 applied nanotechnology as a strategy for biofilm control; however, only 12 specifically addressed nanopharmaceutical formulations for the treatment of biofilms. Conclusion: Microbial biofilms play a crucial role in chronic and recurrent infections. Antibiotic treatment alone is often inadequate for the complete eradication of biofilm-associated infections, contributing to high recurrence rates and unsatisfactory clinical outcomes. This review highlights promising new drug candidates as potential strategies for the treatment of biofilm-associated infections.
Referências
ALVAREZ D, et al. Prospecting peptides isolated from black soldier fly (Diptera: Stratiomyidae) with antimicrobial activity against Helicobacter pylori (Campylobacterales: Helicobacteraceae). Journal of Insect Science. 2019;19(6):17.
BARENHOLZ Y, et al. Doxil® — the first FDA-approved nano-drug: lessons learned. Journal of Controlled Release. 2012;160(2):117–134.
BISWARO LS, et al. Antimicrobial peptides and nanotechnology: recent advances and challenges. Frontiers in Microbiology. 2018;9:855.
DE LA FUENTE-NÚÑEZ C, et al. D-enantiomeric peptides that eradicate wild-type and multidrug-resistant biofilms and protect against lethal Pseudomonas aeruginosa infections. Chemistry & Biology. 2015;22(2):196–205.
SOUZA GHA, et al. Antimicrobial peptides against polymyxin-resistant Klebsiella pneumoniae: a patent review. World Journal of Microbiology & Biotechnology. 2023;39(3):86.
EWII UE, et al. Nanoparticles for drug delivery: insight into in vitro and in vivo drug release from nanomedicines. Nano TransMed. 2025;4:100083.
FACCIN ID, et al. New therapeutic options for fusariosis: a patent review (2008–2023). Journal of Fungi. 2025;11(6):463.
FARHADI K, et al. Thymol and carvacrol against Klebsiella: antibacterial, antibiofilm and synergistic activities — a systematic review. Frontiers in Pharmacology. 2024;15:1487083.
KAREEM YM, et al. Assessment of the antibacterial effect of barium titanate nanoparticles against Staphylococcus epidermidis adhesion after addition to maxillofacial silicone. F1000Research. 2023;12:385.
LE H, et al. Antibody-conjugated nanocarriers for targeted antibiotic delivery: application in the treatment of bacterial biofilms. Biomacromolecules. 2021;22(4):1639–1653.
LIU Q, et al. Current research trends of nanomedicines. Acta Pharmaceutica Sinica B. 2023;13(11):4391–4416.
MANSOUR SC, et al. Bacterial abscess formation is controlled by the stringent stress response and can be targeted therapeutically. EBioMedicine. 2016;12:219–226.
MOHAMAD F, et al. An explorative review on advanced approaches to overcome bacterial resistance by curbing bacterial biofilm formation. Infection and Drug Resistance. 2023;16:19–49.
MOLAEITABARI A, et al. Blocking the shikimate pathway amplifies the impact of carvacrol on biofilm formation in Candida albicans. Microbiology Spectrum. 2025;13(3):e0275424.
MORETTA A, et al. A bioinformatic study of antimicrobial peptides identified in the black soldier fly (Hermetia illucens). Scientific Reports. 2020;10(1):16875.
MURRAY CJL, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022;399(10325):629–655.
SÁNCHEZ IC, et al. Essential oils from Colombian Croton spp. exhibit antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and resistant Escherichia coli. Scientific Reports. 2024;14(1):30643.
SERTKAYA A, et al. Assessing the state of antibacterial drug discovery through patent analysis. International Journal of Antimicrobial Agents. 2024;63(2):107051.
SRINIVASAN R, et al. Bacterial biofilm inhibition: a focused review on recent therapeutic strategies for combating biofilm-mediated infections. Frontiers in Microbiology. 2021;12.
VENTOLA CL, et al. Progress in nanomedicine: approved and investigational nanodrugs. Pharmacy and Therapeutics. 2017;42(12):742–755.
WALSH TR, et al. Antimicrobial resistance: addressing a global threat to humanity. PLOS Medicine. 2023;20(7):e1004264.
XIA J, et al. Antimicrobial peptides from black soldier fly (Hermetia illucens) as potential antimicrobial factors representing an alternative to antibiotics in livestock farming. Animals. 2021;11(7):1937.
YANG Z, et al. Classical and modern models for biofilm studies: a comprehensive review. Antibiotics. 2024;13(12):1228.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
- O conteúdo dos artigos é de responsabilidade exclusiva dos autores.
- É permitida a reprodução total ou parcial do conteúdo dos artigos, desde que citada a fonte.
- Artigos com plágio serão recusados, e o autor do plágio perderá o direito de publicar nesta revista.
- Os nomes e endereços informados nesta revista serão utilizados exclusivamente para os serviços prestados por esta publicação e não estão disponíveis para outros fins ou a terceiros.
- Depois de enviar os artigos, os autores cedem os direitos autorais de seus artigos ao BJAER. Se você se arrepender da submissão, o autor tem o direito de solicitar ao BJAER que não publique seu artigo. Porém, essa solicitação deve ocorrer até dois meses antes da divulgação do número que o artigo será publicado.
- O BJAER usa a licença Creative Commons CC BY. Informações sobre esta licença podem ser encontradas em: https://creativecommons.org/licenses/by/3.0/br/
Brazilian Journal of Animal and Environmental Research (BJAER) se reserva o direito de efetuar nos originais alterações de ordem normativa, ortográfica e gramatical, com vistas a manter o padrão culto da língua, respeitando, porém, o estilo dos autores. Os trabalhos finais não serão enviadas aos autores.
